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Abstract. 
 
Platelets respond to various stimuli with 
rapid changes in shape followed by aggregation and se-
cretion of their granule contents. Platelets lacking the 
 
a
 
-subunit of the heterotrimeric G protein G
 
q
 
 do not ag-
gregate and degranulate but still undergo shape change 
after activation through thromboxane-A
 
2 
 
(TXA
 
2
 
) or 
thrombin receptors. In contrast to thrombin, the TXA
 
2
 
 
mimetic U46619 led to the selective activation of G
 
12
 
 
and G
 
13
 
 in G
 
a
 
q
 
-deficient platelets indicating that these 
G proteins mediate TXA
 
2
 
 receptor-induced shape 
change. TXA
 
2
 
 receptor-mediated activation of G
 
12
 
/G
 
13
 
 
resulted in tyrosine phosphorylation of pp72
 
syk
 
 and 
stimulation of pp60
 
c-src
 
 as well as in phosphorylation of 
myosin light chain (MLC) in G
 
a
 
q
 
-deficient platelets. 
Both MLC phosphorylation and shape change induced 
through G
 
12
 
/G
 
13
 
 in the absence of G
 
a
 
q
 
 were inhibited 
by the C3 exoenzyme from 
 
Clostridium botulinum
 
, by 
the Rho-kinase inhibitor Y-27632 and by cAMP-ana-
logue Sp-5,6-DCl-cBIMPS. These data indicate that 
G
 
12
 
/G
 
13
 
 couple receptors to tyrosine kinases as well as 
to the Rho/Rho-kinase—mediated regulation of MLC 
phosphorylation. We provide evidence that G
 
12
 
/G
 
13
 
-
mediated Rho/Rho-kinase—dependent regulation of 
MLC phosphorylation participates in receptor-induced 
platelet shape change.
Key words: platelet ¥ platelet shape change ¥ G pro-
tein ¥ Rho-kinase ¥ myosin light chain phosphorylation
T
 
HE
 
 functional responses of platelets to various full
platelet activators are well characterized and in-
clude secretion of granular contents, platelet aggre-
gation, and platelet shape change. Platelets are discoid in
their resting state and upon activation by most stimuli rap-
idly change into a spheroid shape and extrude pseudopo-
dia. This shape change is one of the earliest effects detect-
able in response to various platelet stimuli. Platelet shape
change is believed to be a prerequisite for full platelet acti-
vation including degranulation and aggregation. The acti-
vation of platelets is responsible for primary hemostasis
and underlies various pathological situations such as un-
stable angina pectoris, myocardial infarction, or cerebro-
vascular diseases.
Platelet shape change results from a rapid reorganiza-
tion of the cytoskeleton including formation of new actin
filaments, disappearance of the marginal band of microtu-
bules, and centralization of granules (Siess, 1989; Wur-
zinger, 1990; Fox, 1993; Morgenstern, 1997). Signal trans-
duction mechanisms regulating platelet shape change are
ill defined. An involvement of tyrosine phosphorylation
events, myosin light chain phosphorylation and polyphos-
phoinositide-induced actin polymerization have been sug-
gested (Daniel et al., 1984; Hartwig et al., 1995; Negrescu
et al., 1995; Maeda et al., 1995). Several reports have dem-
onstrated that, in contrast to full platelet activation, induc-
tion of platelet shape change does not require elevation of
the free cytosolic Ca
 
2
 
1
 
 concentration (Rink et al., 1982;
Simpson et al., 1986; Ohkubo et al., 1996). Consistent with
 
that, we recently demonstrated that incubation of G
 
a
 
q
 
-
deficient platelets with various stimuli failed to induce
 
phospholipase C activation and [Ca
 
2
 
1
 
]
 
i
 
 elevation as well
as aggregation and degranulation. Platelet shape change,
however, could still be elicited (Offermanns et al., 1997b).
Platelets do not contain G
 
a
 
11
 
, a close homologue of G
 
a
 
q
 
(Milligan et al., 1993; Johnson et al., 1996; Offermanns et al.,
1997b).
The effect of full platelet stimuli like thromboxane A
 
2
 
(TXA
 
2
 
)
 
1
 
 and thrombin are mediated through G protein—
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Abbreviations used in this paper: 
 
MLC, myosin light chain; MLCK, my-
osin light chain kinase; GEF, guanine nucleotide exchange factor; TXA
 
2
 
,
thromboxane A
 
2
 
.
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coupled receptors which have been shown to activate G
 
q
 
,
G
 
i
 
, G
 
12
 
, and G
 
13
 
 (Shenker et al., 1991; Hung et al., 1992;
Offermanns et al., 1994; Ushikubi et al., 1994). G proteins
are heterotrimers which are defined by their 
 
a
 
-subunits.
According to structural and functional similarities, G pro-
tein 
 
a
 
-subunits are grouped into four families, G
 
a
 
q
 
, G
 
a
 
i
 
,
G
 
a
 
12
 
, and G
 
a
 
s
 
 (Simon et al., 1991). Although G
 
q
 
-mediated
activation of phospholipase C 
 
b
 
-isoforms appears to play a
central and essential role in agonist-induced platelet ag-
gregation and secretion, G
 
i
 
-type G proteins are involved
in the inhibitory regulation of platelet adenylyl cyclase
(Brass et al., 1997, 1988; Offermanns et al., 1997b). The
role of the G
 
12
 
 family members, G
 
12
 
 and G
 
13
 
, in the regula-
tion of platelet function is unclear. The 
 
a
 
-subunits of both
G proteins appear to be involved in the regulation of cell
growth and cell movement (Dhanasekaran and Dermott,
1996; Offermanns et al., 1997a). Since G
 
12
 
/G
 
13
 
-coupled re-
ceptors appear to also activate G
 
q
 
 family members it has
been difficult to selectively study the cellular signaling
processes regulated by receptor-mediated activation of
G
 
12
 
/G
 
13
 
. Most knowledge about the signaling pathways in-
fluenced by G
 
12
 
/G
 
13
 
 results from the use of constitutively
active forms of G
 
a
 
12
 
 and G
 
a
 
13
 
. Either mutant has been
shown to cause Na
 
1
 
/H
 
1
 
 exchanger activation, stimulation
of phospholipase D, cell transformation, and formation of
actin stress fibers through the small molecular weight GTP-
ase Rho (Buhl et al., 1995; Hooley et al., 1996; Fromm et al.,
1997; Plonk et al., 1998). The effector directly regulated by
G
 
a
 
12
 
 and G
 
a
 
13
 
 has been elusive. However, the guanine nu-
cleotide exchange factor (GEF) for Rho, p115RhoGEF,
has been shown to interact with G
 
a
 
12
 
 and G
 
a
 
13
 
 and repre-
sents a candidate effector (Kozasa et al., 1998; Hart et al.,
1998).
To study the possible role of G
 
12
 
/G
 
13
 
 in the platelet
shape change response we took advantage of platelets
from G
 
a
 
q
 
-deficient mice. In this report, we demonstrate
that selective activation of G
 
12
 
/G
 
13
 
 is sufficient to induce
the platelet shape change reaction, and we provide evi-
dence that this involves Rho/Rho-kinase—mediated phos-
phorylation of the myosin light chain.
 
Materials and Methods
 
Materials
 
U46619 was from Cayman Chemical, thrombin, histone (subgroup f2b),
monoclonal anti-myosin light chain (MLC) antibody, and fluorescein
isothiocyanate (FITC)-phalloidin were from Sigma. Sp-5,6-DCl-cBIMPS
and 8-pCPT-cGMP were from Biolog. Y-27632 was kindly provided by
Yoshitomi Pharmaceutical Industries, 
 
Clostridium botulinum
 
 C3-exoen-
zyme was a donation from I. Just and K. Aktories (both from University
of Freiburg, Freiburg, Germany) or was purchased from Upstate Biotech-
nologies, anti-pp72
 
syk
 
 antibodies as well as anti-phosphotyrosine antibod-
ies were from Santa Cruz Biotechnology, and anti-pp60
 
v-src
 
 antibodies
were from Oncogene. Antisera against G protein 
 
a
 
-subunits have been
described (Offermanns et al., 1994; Laugwitz et al., 1994).
 
Platelet Preparation and Aggregation
 
Whole blood was collected from normal and G
 
a
 
q
 
-deficient mice anesthe-
tized with pentobarbital by puncturing the inferior vena cava with hep-
arinized syringes at a final concentration of 25 U heparin/ml blood. The
blood from three or four G
 
a
 
q
 
-deficient mice and wild-type mice was
pooled for each platelet aggregation experiment. Blood was diluted with
half the volume of Hepes-Tyrode-buffer (134 mM NaCl, 0.34 mM
 
Na
 
2
 
HPO
 
4
 
, 2.9 mM KCl, 12 mM NaHCO
 
3
 
, 20 mM Hepes, 5 mM glucose,
1 mM MgCl
 
2
 
, pH 7.3), and platelet rich plasma (PRP) was obtained by
centrifugation for 7.5 min at 250 
 
g
 
. Thereafter, prostacyclin at a final con-
centration of 300 nM was added to the PRP, and platelets were pelleted
by centrifugation at 1,200 
 
g
 
 for 5 min. The platelet pellet was resuspended
in Hepes-Tyrode buffer and incubated for 30 min at 37
 
8
 
C. Platelet suspen-
sion was adjusted to 300,000 platelets per microliter with Hepes-Tyrode
buffer. Optical aggregation experiments were conducted in a four-channel
aggregometer (model Aggrecorder II PA-3220; Kyoto Daiichi Kagaku).
Preincubation in Hepes-Tyrode buffer without and with cGMP and
cAMP analogues and Y-27632 was performed for 20 min at room temper-
ature. Immediately before the aggregation experiments, platelets were
preincubated for 1 min at 37
 
8
 
C in Hepes-Tyrode buffer containing 1 mM
CaCl
 
2
 
.
 
Photolabeling of Membrane Proteins and 
Immunoprecipitation of G
 
a
 
-subunits
 
Platelet membranes were prepared and photolabeled as described (Offer-
manns et al., 1994). In brief, cell membranes (50—100 
 
m
 
g of protein per as-
say tube) were incubated at 30
 
8
 
C in a buffer containing 0.1 mM EDTA,
10 mM MgCl
 
2
 
, 30 mM NaCl, 1 mM benzamidine, and 50 mM Hepes-
NaOH, pH 7.4. After 3 min of preincubation in the absence and presence
of receptor agonist, samples were incubated for another 15 min with 10—20
nM [
 
a
 
-
 
32
 
P]GTP azidoanilide (130 kBq per tube). [
 
a
 
-
 
32
 
P]GTP azidoanilide
was synthesized and purified as described (Offermanns et al., 1991). For
photolabeling of G
 
i
 
 
 
a
 
-subunits, 5 
 
m
 
M GDP was present in the incubation
buffer. Samples were washed, dissolved in labeling buffer, and then irradi-
ated as described (Offermanns et al., 1994). Photolabeled membranes
were pelleted and proteins were predenatured in SDS. Solubilized mem-
branes were preabsorbed with protein A—Sepharose beads, and immuno-
precipitation was done as described (Laugwitz et al., 1994).
 
SDS-PAGE and Immunoblotting
 
SDS-PAGE of photolabeled proteins was performed on 10% (wt/vol)
acrylamide gels. Photolabeled membrane proteins were visualized by au-
toradiography of the dried gels. Blotting of membrane proteins separated
by SDS-PAGE, processing of immunoblots, and detection of immunore-
active proteins by chemiluminescence procedure (Amersham) has been
described (Laugwitz et al., 1994).
 
Determination of Cellular cAMP Levels
 
Platelets (10
 
8
 
 per tube) were preincubated for 15 min with 300 
 
m
 
M 3-iso-
butyl-1-methylxanthine and 20 
 
m
 
M 4-(3-butoxy-4-methoxybenzyl)-2-imid-
azolidinone (Ro 20-1724) and incubated for 20 min in the absence and
presence of receptor agonists. The reaction was stopped by the addition of
300 
 
m
 
l of ice-cold 10% (wt/vol) trichloracetic acid. Samples were kept for
10 min on ice, and 180 
 
m
 
l of 1 M Tris, pH 9.8, was added to neutralize the
sample. Cyclic AMP was determined by the competitive-binding assay
(Gilman and Murad, 1974). In brief, samples were incubated for 2 h with 2
pmol of [8-
 
3
 
H]cAMP (925 Gbq/mmol; Amersham) and 62.5 
 
m
 
g of cAMP-
dependent protein kinase purified from porcine heart (Sigma) in a final
volume of 200 
 
m
 
l at 4
 
8
 
C. Then, 4% (wt/vol) charcoal in 5 mM EDTA and
50 mM Tris-HCl, pH 7.5, was added, and samples were immediately cen-
trifuged for 2 min at 12,000 
 
g
 
. Supernatants were counted in a liquid scin-
tillation counter, and the amount of cAMP in the test sample was calcu-
lated as described (Gilman and Murad, 1974).
 
Determination of Tyrosine Phosphorylation
 
Isolated platelets (1—2 
 
3 
 
10
 
7
 
 platelets per tube) were incubated in 40 
 
m
 
l
Hepes-Tyrode buffer at 37
 
8
 
C as indicated. Reactions were stopped by ad-
dition of 20 
 
m
 
l of 3
 
3 
 
sample buffer containing a final concentration of
1 mM Na
 
3
 
VO
 
4
 
. Heated samples were separated by SDS-PAGE on 10%
gels. Immunoblotted proteins were analyzed for phosphotyrosine with an
antiphosphotyrosine antibody.
Immunoprecipitation and Immune Complex
Kinase Assay
For immunoprecipitation of tyrosine kinases pp72syk and pp60c-src, platelet
suspensions (0.4—1 3 109 platelets) were incubated in the absence or pres-
ence of 5 mM U46619 for the indicated time periods, and platelets were
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lysed by addition of an equal volume of ice-cold 23 radioimmunoprecipi-
tation assay (RIPA) buffer (final concentration: 1% Triton X-100, 0.1%
SDS, 1% sodium deoxycholate, 150 mM NaCl, 50 mM Hepes/NaOH, pH
7.4, 3 mM EDTA, 3 mM EGTA, 1 mM sodium orthovanadate, 1 mM phe-
nylmethylsulfonyl fluoride, 20 mg/ml aprotinin, 20 mg/ml leupeptin). After
incubation for 20 min on ice, samples were centrifuged for 20 min at
15,000 g at 48C, and incubated with 5 mg agarose conjugates of rabbit poly-
clonal anti-pp72syk IgG or 8 ml of agarose-conjugated mouse monoclonal
anti-pp60v-src IgG1 for 2 h at 48C. Immunoprecipitates were collected by
centrifugation at 15,000 g for 10 min at 48C and were washed twice with
13 RIPA buffer, once with 1% Triton X-100, 0.3% SDS, 600 mM NaCl,
and 50 mM Tris-HCl, pH 7.4, and once with 300 mM NaCl, 10 mM
EDTA, 100 mM Tris-HCl, pH 7.4. For detection of pp72syk phosphoryla-
tion, precipitated proteins were eluted with 40 ml of 13 SDS sample
buffer and separated by 10% polyacrylamide gels. Tyrosine phosphoryla-
tion of pp72syk and pp72syk protein were analyzed by immunoblotting. The
anti-pp60c-src immunoprecipitates were divided into two aliquots; one was
analyzed by anti-pp60c-src immunoblotting, and the other was subjected to
in vitro kinase assay. To examine in vitro kinase activity, precipitates were
incubated for 5 min at 258C in kinase buffer containing 25 mM Hepes/
NaOH, pH 7.4, 10 mM MnCl2, 1 mM ATP (7 mCi of [g-32P]ATP/tube), and
0.25 mg/ml histone. Reaction was terminated by addition of 23 sample
buffer, and samples were subjected to SDS-PAGE. Phosphorylation of
histone was analyzed by autoradiography of dried gels.
Scanning Electron Microscopy
Isolated platelets were preincubated under the indicated conditions.
Thereafter, platelets were incubated in the absence or presence of 1 U/ml
thrombin or 5 mM U46619 for 5 s at 378C and then fixed for 10 min with
3% paraformaldehyde, 3.75% glutaraldehyde, 0.06 mM cacodylate buffer,
and 3.4 mM CaCl2. The fixed platelets were suction filtered onto polycar-
bonate filters (0.45 mm; Nucleopore) which had been preincubated with
10 mg/ml polylysine. Filters were washed three times with 0.9% NaCl and
dehydrated stepwise in aqueous ethanol. After exchange of ethanol for
hexadimethyldisilazane, samples were air-dried and sputtered with gold.
Scanning electron microscopy was carried out on a Zeiss-Gemini instru-
ment using a beam voltage of 5 kV.
MLC Phosphorylation
MLC phosphorylation was determined as described (Daniel and Sellers,
1992). Isolated platelets (1—2 3 107 platelets per tube) were incubated in
30 ml Hepes-Tyrode buffer at 378C as indicated. Reactions were stopped
by addition of 30 ml of 40% (vol/vol) perchloric acid. Precipitated samples
were kept on ice for 20—30 min. After centrifugation (10 min at 15,000 g at
48C) pellets were washed twice with acetone containing 10 mM DTT. 30 ml
of SDS sample buffer was added to dried samples, and proteins were solu-
bilized by sonication for 30 min. Separation of proteins on urea/glycin gels
was done as described (Daniel and Sellers, 1992), and MLC was detected
after immunoblotting with an anti-MLC antibody.
Determination of F-actin Content
For actin filament content measurements, platelets (108) were incubated
as indicated and fixed in 2% paraformaldehyde for 30 min at 378C. Fixed
platelets were permeabilized with 0.1% Triton X-100, incubated with 10 mM
fluorescein isothiocyanate (FITC)-phalloidin (Sigma) for 30 min at room
temperature and were then washed. Bound FITC-phalloidin was quanti-
fied using a fluorescence spectrophotometer (Perkin-Elmer) (excitation at
495 nm; emission at 519 nm).
ADP Ribosylation of Platelet Lysates by C3 Exoenzyme
Washed platelets were incubated with the indicated concentrations of C3
exoenzyme in Hepes-Tyrode buffer. Platelets were lysed by addition of an
equal volume of lysis buffer (1.5% Triton X-100, 0.8% DOC, 0.2% SDS,
145 mM NaCl, 20 mM Hepes, pH 7.4, 3 mM EGTA, 0.3 mM phenylmeth-
ylsulfonyl fluoride, 5 mM leupeptin, 5 mg/ml aprotinin). ADP-ribosylation
using [32P]NAD was performed as described (Morii et al., 1992), and ribo-
sylated samples were separated on 12% polyacrylamide gels.
Results
We have recently shown that Gaq-deficient platelets do
not aggregate and secrete their granule contents in re-
sponse to various stimuli indicating that Gq-mediated acti-
vation of phospholipase C represents the central early sig-
nal transduction process leading to full platelet activation.
However, Gq-deficient platelets were still able to undergo
ligand-induced platelet shape change. This suggests that G
proteins other than Gq mediate the platelet shape change
response. Shape change induced by the TXA2 analogue
U46619 could be observed in Gaq-deficient platelets by
scanning electron microscopy of single cells (Fig. 1, A—D)
Figure 1. Scanning electron microscopy of
inactivated and activated wild-type and
Gaq-deficient platelets. Wild-type plate-
lets (A, B, E, F, I, and J) and Gaq-defi-
cient platelets (C, D, G, H, K, and L) were
preincubated for 30 min in the absence
(A—D) or presence of 10 mM Y-27632
(E—H) or were pretreated for 2 h with 50
mg/ml C3 exoenzyme (I—L). Thereafter,
platelets were incubated for 5 s in the ab-
sence (A, C, E, G, I, and K) and presence
of 5 mM U46619 (B, D, F, H, J, and L),
fixed, and then analyzed as described in
Materials and Methods. Platelets incubated
for 2 h in C3-exoenzyme buffer alone
showed normal shape change in response
to U46619 (data not shown). Bar, 1 mm.
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as well as by measuring the light transmission of a platelet
suspension (Fig. 2). Shape change induced by U46619 in
Gaq-deficient platelets and wild-type platelets was blocked
by the cAMP analogue Sp-5,6-DCl-cBIMPS but not by the
cGMP analogue 8-pCPT-cGMP, whereas both cyclic nu-
cleotides blocked aggregation in wild-type platelets (Fig.
2, A and B). Similar results were observed with thrombin-
activated wild-type and Gaq-deficient platelets (data not
shown). Preincubation of platelets with the recently de-
scribed Rho-kinase inhibitor Y-27632 (Uehata et al.,
1997) blocked U46619-induced shape change both in wild-
type and Gaq-deficient platelets (Fig. 1, E—H and Fig. 2, C
and D). To assess the role of Rho in agonist-induced plate-
let shape change we preincubated platelets for 2 h with
50 mg/ml C3 exoenzyme which ADP ribosylates and inac-
tivates the small GTPase Rho (Morii et al., 1992). This C3
exoenzyme concentration and preincubation time resulted
in ADP-ribosylation of 70—75% of endogenous Rho as de-
termined by the inability of C3 exoenzyme to [32P]ADP-
ribosylate Rho in subsequently prepared cell lysates (Fig.
3). Longer preincubation times and higher C3 exoen-
zyme concentrations further increased the ADP-ribosy-
lated fraction of Rho (Fig. 3), but resulted in preactiva-
tion of platelets (data not shown). C3-pretreated platelets
showed markedly reduced shape change in response to
U46619 with only partial spheration and occasional filopo-
dia formation (Fig. 1, I—L and Fig. 2 E).
Since platelet shape change including protrusion of
filopodia and lamellipodia is accompanied by actin poly-
merization (Siess, 1989; Wurzinger, 1990; Fox, 1993) we
measured F-actin content in wild-type and Gaq-deficient
platelets (Fig. 4). U46619 induced an increase in F-actin
content of both, wild-type and Gaq-deficient platelets,
which could be completely blocked by Y-27632. Reduction
of the amount of functional Rho by pretreatment with 50
mg/ml C3 exoenzyme for 2 h markedly reduced the effect
of U46619 in wild-type and Gaq-deficient platelets.
To identify the G proteins mediating receptor-induced
platelet shape change we studied the coupling of TXA2
and thrombin receptors to heterotrimeric G proteins in
wild-type and Gaq-deficient mouse platelets. Receptors
for both, thrombin and TXA2, have been shown to be able
to couple to members of the Gq, G12, and Gi families
(Shenker et al., 1991; Hung et al., 1992; Offermanns et al.,
1994; Ushikubi et al., 1994). In membranes of human
platelets, receptors activated by thrombin couple to Gq,
G12, G13, and Gi, whereas TXA2 receptors only activate
Gq, G12, and G13 (Offermanns et al., 1994; Brass et al.,
1997). Photolabeling of receptor-activated G proteins in
mouse platelet membranes and subsequent immunopre-
cipitation of individual G protein a-subunits showed that
in wild-type mouse platelets, activated TXA2 and throm-
bin receptors couple to Gq, G12, and G13, whereas Gi was
only activated through the thrombin receptor (Fig. 5 A).
Figure 2. Aggregation response of wild-type and Gaq-deficient
platelets. Wild-type platelets (B and D) and platelets from Gaq
(2/2) mice (A, C, and E) were preincubated for 20 min with the
indicated concentrations of 8-pCPT-cGMP (pCPT-cGMP) or Sp-
5,6-DCl-cBIMPS (cBIMPS) (A and B) or for 30 min with the in-
dicated concentrations of Y-27632 (C and D), and Gaq-deficient
platelets were preincubated for 2 h in the absence or presence of
C3 exoenzyme (E). Thereafter, incubation was started by the ad-
dition of 5 mM U46619. Shown is the relative light transmission
through the platelet suspension. 0% represents transmission
through the platelet suspension before addition of U46619, and
100% represents transmission through the buffer alone. Upward
movements of the curve show decreases in light transmission in-
dicating platelet shape change. Addition of stimuli is signified by
the arrows, 3-min traces are shown.
Figure 3. ADP ribosylation
of Rho in C3-treated plate-
lets. (A) Platelets from wild-
type and Gaq-deficient ani-
mals were preincubated for 2 h
in the absence (2) or pres-
ence of the indicated concen-
trations of C3 exoenzyme.
Thereafter, platelets were
lysed and subjected to C3-
exoenzyme catalyzed (32P)
ADP ribosylation as de-
scribed under Materials and
Methods. Shown is an auto-
radiogram with the position
of the 21-kD standard pro-
tein on the left. (B) Densito-
metric evaluation of bands
shown in A. Bars represent
mean of two independent ex-
periments as percent of con-
trol.
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Similarly, in membranes from Gaq-deficient platelets, only
G12 and G13 were activated through the TXA2 receptor,
whereas activated thrombin receptors coupled to G12, G13,
and Gi (Fig. 5 B and data not shown). Coupling of throm-
bin receptors to Gi in murine platelets corresponded with
the ability of thrombin to decrease cAMP levels in wild-
type as well as in Gaq-deficient platelets, whereas activa-
tion of TXA2 receptors had no effect on adenylyl cyclase
activity in wild-type or Gaq-deficient platelets (data not
shown). These data clearly demonstrate that in Gaq-defi-
cient platelets thrombin-receptors couple to G12, G13, and
Gi, whereas only G12 and G13 are activated through TXA2
receptors. Consequently, effects which can still be induced
by TXA2 receptor agonists in Gaq-deficient platelets like
the shape change response are mediated by G12 and/or
G13. TXA2-activated Gaq-deficient platelets therefore rep-
resent a model to study of G12/G13-mediated signaling pro-
cesses.
Agonist-induced platelet activation results in tyrosine
phosphorylation of multiple proteins (Ferrell and Martin,
1988; Nakamura and Yamamura, 1989; Golden and Brugge,
1989). Phosphorylation of these proteins occurs in three
temporal phases which have been experimentally distin-
guished. Early tyrosine phosphorylation occurs by an in-
tegrin-independent mechanism, whereas the second and
third wave of tyrosine phosphorylation depends on the ag-
gregation of platelets through binding of fibrinogen to
aIIbb3-integrin (glycoprotein IIb-IIIa) (Clark et al., 1994b).
In Gaq-deficient platelets that do not aggregate in re-
sponse to thrombin or U46619, only a subset of proteins
became tyrosine phosphorylated upon exposure of plate-
lets to both stimuli compared with wild-type platelets (Fig.
6, A and B). Most prominently, a rapid tyrosine phosphor-
ylation of a protein of z72 kD could be observed in Gaq-
deficient platelets activated with thrombin and U46619. In
contrast, several proteins with relative molecular masses
of 40 and 95—130 kD which were tyrosine phosphorylated
in wild-type platelets did not show increased tyrosine
phosphorylation in activated Gaq-deficient platelets (Fig.
6, A and B).
Platelets contain several tyrosine kinases (Dhar and
Shukla, 1993; Clark et al., 1994b; Jackson et al., 1996)
among which pp72syk and pp60c-src are rapidly activated af-
ter stimulation of platelets in an aggregation-independent
manner (Wong et al., 1992; Taniguchi et al., 1993; Maeda
et al., 1993; Clark and Brugge, 1993; Clark et al., 1994a).
To test whether the 72-kD protein that was tyrosine phos-
phorylated in response to U46619 and thrombin in Gaq-
deficient platelets represented pp72syk, we immunoprecipi-
tated pp72syk from lysates of platelets exposed to U46619.
Anti-phosphotyrosine immunoblots of pp72syk immuno-
precipitates demonstrated increased tyrosine phosphory-
lation of pp72syk in response to U46619 in Gaq-deficient
platelets as well as in wild-type platelets (Fig. 6 C). Auto-
phosphorylation of pp72syk on tyrosine has been demon-
strated to increase its enzymatic activity (Taniguchi et al.,
1993; Clark et al., 1994a; Chacko et al., 1994; Fujii et al.,
1994). Fig. 6 C shows that incubation of wild-type and
Gaq-deficient platelets with U46619 also resulted in a
rapid increase in the activity of pp60c-src. Increases in ty-
rosine kinase activity could be observed within 10 s after
addition of U46619 and were not affected by pretreatment
of platelets with Y-27632 or C3 exoenzyme (data not
shown). These data indicate that TXA2 receptor-mediated
activation of G12/G13 leads to rapid activation of the ty-
rosine kinases pp72syk and pp60c-src in mouse platelets.
MLC phosphorylation has been suggested to be in-
volved in early processes during platelet activation (Dan-
iel et al., 1984). To test whether TXA2 receptor-G12/G13—
mediated signaling in Gaq-deficient platelets resulted in
Figure 4. Determination of F-actin content. Wild-type and Gaq-
deficient platelets were preincubated for 30 min in the absence
(c) or presence of 10 mM Y-27632 (Y) or were pretreated for 2 h
with 50 mg/ml C3 exoenzyme (C3). Thereafter, platelets were in-
cubated for 10 s in the absence (2) or presence of 5 mM U46619
(1), fixed, and then incubated with fluorescein isothiocyanate
(FITC)-phalloidin. Platelets incubated for 2 h in C3 exoenzyme
buffer alone showed full increase in F-actin content in response
to U46619 (data not shown). F-actin content was determined as
described in Materials and Methods. Shown are means 6 SD of
triplicates.
Figure 5. Receptor-depen-
dent activation of G proteins
in membranes of wild-type
and Gaq-deficient platelets.
Membranes from wild-type
(A) and Gaq-deficient plate-
lets (B) were photolabeled
with [a-32P]GTP azidoani-
lide in the absence (2) or
presence of 5 mM U46619 or
5 U/ml thrombin (1). Mem-
branes were solubilized and
G protein a-subunits (Ga12,
Ga13, Gaq, and Gai) were
immunoprecipitated as de-
scribed under Materials and
Methods. Anti-Ga12, anti-
Ga13, anti-Gaq/11 antisera,
and an antiserum recognizing
Gai1, Gai2, and Gai3 were used. Precipitated proteins were sub-
jected to SDS-PAGE. Shown are autoradiograms of dried SDS
gels with the position of the 43-kD standard protein shown on the
left.
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MLC phosphorylation, we activated platelets with U46619
for different times and separated phosphorylated and un-
phosphorylated MLC on urea/glycin polyacrylamide gels.
Separated proteins were blotted onto nitrocellulose filters
and MLC was detected using a specific antiserum. Fig. 7 A
shows that U46619 caused phosphorylation of the total de-
tectable pool of MLC in wild-type platelets within 10 s. In-
terestingly, a rapid and apparently complete phosphoryla-
tion of MLC was also observed in Gaq-deficient platelets
activated by U46619. Chelation of extracellular Ca21 by
EGTA or preincubation of platelets with various tyrosine
kinase inhibitors had no effect on U46619-induced MLC
phosphorylation in wild-type and Gaq-deficient platelets
(data not shown). Although the cAMP analogue Sp-5,6-
DCl-cBIMPS completely inhibited MLC phosphorylation
in wild-type and Gaq-deficient platelets the cGMP analogue
8-pCPT-cGMP was without effect (Fig. 7, B and C). In
smooth muscle cells and fibroblasts, the phosphorylation
state of MLC has been shown to be under dual control
of the Ca21/calmodulin-activated myosin light chain ki-
nase (MLCK) as well as of myosin-phosphatase (Somlyo
and Somlyo, 1994; Burridge and Chrzanowska-Wodnicka,
1996). Myosin-phosphatase has been demonstrated to be
regulated by Rho/Rho-kinase (Kimura et al., 1996; Naru-
miya et al., 1997). Since U46619-induced platelet shape
change was blocked by the Rho-kinase inhibitor Y-27632
and was greatly inhibited after reduction of the amount of
active Rho by C3 exoenzyme (Figs. 1 and 2) we tested the
effect of C3 exoenzyme and Y-27632 on U46619-induced
phosphorylation of MLC. Fig. 7, D—F shows that Y-27632
blocked and C3 exoenzyme markedly inhibited U46619-
induced MLC-phosphorylation in wild-type as well as in
Gaq-deficient platelets. Incomplete inhibition of MLC
phosphorylation by C3 exoenzyme was most likely due to
incomplete inactivation of Rho by C3 exoenzyme (see
Fig. 3). Y-27632 exerted its inhibitory effect on receptor-
induced MLC phosphorylation with higher potency in
Gaq-deficient platelets compared with wild-type platelets
(Fig. 7, D and E). Similarly, the effect of C3 exoenzyme
appeared to be more pronounced in the absence of Gaq
(Fig. 7 F). These data indicate that activation of G12/G13
through the TXA2 receptor results in MLC phosphoryla-
tion and that this process involves Rho/Rho-kinase. The
data also provide further evidence for the concept that
MLC phosphorylation underlies platelet shape change.
Discussion
Full platelet activators like TXA2 and thrombin function
through G protein—coupled receptors which activate Gq,
G12, G13, and Gi type G proteins (Shenker et al., 1991;
Hung et al., 1992; Ushikubi et al., 1994; Offermanns et al.,
1994). Ga11, a close homologue of Gaq and coexpressed
with Gaq in most cells, is not present in platelets (Milligan
et al., 1993; Johnson et al., 1996; Offermanns et al., 1997b).
In Gaq-deficient platelets, the TXA2 mimetic U46619 and
thrombin fail to induce platelet aggregation and degranu-
lation. This is accompanied by a lack of phospholipase C
activation and Ca21 mobilization after TXA2 and throm-
bin receptor activation supporting the concept that Gq-
mediated phospholipase C activation represents the main
signaling process leading to full platelet activation (Offer-
manns et al., 1997b). Lack of Gaq-mediated phospholipase
C activation did not interfere with the ability of U46619
and thrombin to induce platelet shape change as shown by
scanning electron microscopy of activated Gaq-deficient
platelets (see Fig. 1) and measurement of light transmis-
sion through a suspension of Gaq-deficient platelets (see
Fig. 2) (Offermanns et al., 1997b). Thus, induction of
Figure 6. Effect of thrombin and U46619 on tyrosine phosphory-
lation and pp72syk and pp60c-src-activity in wild-type and Gaq-
deficient platelets. (A) Wild-type and Gaq-deficient platelets
were incubated for 30 s in the absence (2) or presence of 5 U/ml
thrombin (Thr.) or 5 mM U46619 (TXA2). (B) Wild-type and
Gaq-deficient platelets were incubated for the indicated times in
the absence (2) or presence of 5 mM of the thromboxane A2 mi-
metic U46619 (T). Cells were lysed and cellular proteins were
separated by SDS-PAGE and blotted on nitrocellulose filters.
Phosphotyrosine was detected by an antiphosphotyrosine anti-
body. Shown are autoluminograms with the position of standard
proteins shown on the left. (C) Wild-type (left) and Gaq-deficient
platelets (right) were incubated with buffer (2) or 5 mM U46619
(1) for the indicated times. Platelets were lysed and incubated
with agarose conjugates of anti-pp72syk IgG (IP: Syk) or of anti-
pp60c-src IgG (IP: Src), and immunoprecipitates were analyzed by
immunoblotting with antiphosphotyrosine antibodies (WB: P-Y),
anti-pp72syk antibodies (WB: Syk), anti-pp60c-src antibodies (WB:
Src), or were subjected to in vitro kinase assays using histone as a
substrate (Histone-P).
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platelet shape change through receptors of different plate-
let stimuli is mediated by G proteins other than Gq, and
Gaq-deficient platelets provide a good model to study the
mechanisms underlying receptor-induced shape change in-
dependently of secondary processes involving secretion
and aggregation.
To identify the G proteins mediating platelet shape
change we studied the coupling of TXA2 and thrombin re-
ceptors to G12 family members and Gi-type G proteins.
Studies in human platelets have provided evidence that
thrombin receptors but not TXA2 receptors couple to Gi-
type G proteins resulting in an inhibition of adenylyl cy-
clase (Aktories and Jakobs, 1984; Houslay et al., 1986;
Brass et al., 1988; Offermanns et al., 1994). Similarly, in mem-
branes from wild-type and Gaq-deficient mouse platelets,
thrombin increased incorporation of GTP-azidoanilide
into Gi, whereas U46619 was without effect (see Fig. 5).
Only thrombin was able to decrease cAMP-levels in wild-
type and Gaq-deficient platelets (data not shown). The
fact that thrombin but not TXA2-receptors couple to Gi
in mouse platelets clearly demonstrates that Gi-mediated
processes do not play a significant role in the regulation of
platelet shape change. Both activated TXA2 (see Fig. 5)
and thrombin receptors (data not shown), coupled to G12
and G13 in wild-type and Gaq-deficient platelets. Thus, in
Gaq-deficient platelets, the only G proteins found to be
activated through TXA2 receptors were G12 and G13. We
therefore conclude that G12 and/or G13 are the mediators
of ligand-induced platelet shape change and that platelet
shape change induced through TXA2 receptors in Gaq-
deficient platelets can be regarded as a G12/G13-regulated
physiological cellular function.
The signaling mechanisms regulating receptor-depen-
dent platelet shape change are incompletely understood.
Elevation of the cytosolic Ca21 concentration is necessary
for full platelet activation including granule secretion and
aggregation. However, there is good evidence that eleva-
tion of [Ca21]i alone is not sufficient to induce platelet
shape change and that agonists can induce shape change
without an increase in phospholipase C activity and with-
out an increase in [Ca21]i (Simpson et al., 1986; Negrescu
et al., 1995; Ohkubo et al., 1996; Offermanns et al., 1997b).
Tyrosine phosphorylation of various proteins has been
associated with receptor-mediated induction of platelet
shape change since this occurs rapidly in a Ca21- and
aIIbb3-integrin—independent manner (Clark et al., 1994b;
Negrescu and Siess, 1996). The mechanism of early recep-
tor-induced tyrosine phosphorylation is not known. Ty-
rosine kinases like pp72syk and pp60c-src, which are rapidly
activated in a partially aIIbb3-integrin—independent man-
ner, may be involved (Clark et al., 1994b; Presek and Mar-
tinson, 1997), and pp72syk has been implicated in the plate-
let shape change response in porcine platelets (Maeda et al.,
1995). However, there is clear evidence that activation of
pp72syk alone is not sufficient for induction of shape change
(Negrescu and Siess, 1996). We show here that TXA2-
receptor—mediated activation of G12/G13 leads to tyrosine
phosphorylation of pp72syk and activation of pp60c-src (see
Fig. 6) supporting the concept that these tyrosine kinases
are involved in early platelet activation. These data also
indicate that G proteins of the G12-family can regulate ty-
rosine kinases. The mechanism of this regulation remains
unknown.
MLC phosphorylation has been implicated in the regu-
lation of cytoskeletal reorganization during platelet shape
change (Daniel et al., 1984; Nachmias et al., 1985). Phos-
phorylated myosin interacts mainly with central actin fila-
ments in platelets, and the forming myosin—actin complex
has been suggested to be involved in the granule central-
ization process (Fox and Phillips, 1982; Stark et al., 1991;
Fox, 1993). The phosphorylation state of MLC is under
dual control of MLCK and myosin-phosphatase. It is well
Figure 7. U46619-induced MLC phosphor-
ylation in wild-type and Gaq-deficient
platelets. (A) Wild-type and Gaq-deficient
platelets were incubated for the indicated
time periods with buffer (c) or 5 mM
U46619 (U). (B and C) Platelets were pre-
incubated for 20 min without or with the
synthetic cyclic nucleotides 8-pCPT-
cGMP (cGMP) or Sp-5,6-DCl-cBIMPS
(cAMP) at the indicated concentrations.
Thereafter, platelets were incubated for
10 s with buffer (c) or 5 mM U46619 (U).
(D and E) Platelets were preincubated for
30 min without or with the Rho-kinase in-
hibitor Y-27632 at the indicated concen-
trations (30 or 100 mM for wild-type and
10 or 30 mM for Gaq-deficient platelets).
Incubation was conducted for 10 s with
buffer (c) or 5 mM U46619 (U). (F) Wild-
type and Gaq-deficient platelets were pre-
incubated for 120 min without (2) or with
50 mg/ml C3 exoenzyme (1). Thereafter,
platelets were incubated for 10 s with buffer (c) or 5 mM U46619 (U). Reactions were stopped by addition of perchloric acid, and phos-
phorylation of MLC was determined using urea/glycin gels as described in Materials and Methods. Shown are autoluminograms of anti-
MLC immunoblots. Phosphorylation of MLC results in a faster mobility (lower position) of MLC on urea/glycin gels.
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established that increase in [Ca21]i activates the Ca21/
calmodulin-dependent MLCK. MLC phosphorylation by
MLCK leads to actin—myosin interaction resulting in ac-
tin-stimulated ATPase activity of smooth muscle and non-
muscle myosin (Somlyo and Somlyo, 1994; Kohama et al.,
1996). Recently, it has been shown that upstream regula-
tion of myosin phosphatase occurs independently of the
cytosolic free calcium concentration through phosphoryla-
tion and inactivation of its regulatory subunit by Rho-
kinase, a specific target of the small GTPase Rho (Ki-
mura et al., 1996; Narumiya et al., 1997). In addition,
Rho-kinase can directly phosphorylate MLC in vitro
(Amano et al., 1996). There is increasing evidence that
Rho/Rho-kinase—mediated MLC phosphorylation is in-
volved in contractile responses in various cell types like
vascular smooth muscle cells (Uehata et al., 1997), fibro-
blasts (Chihara et al., 1997), neuroblastoma cells (Amano
et al., 1998; Hirose et al., 1998), astrocytoma cells (Ma-
jumdar et al., 1998), or endothelial cells (Essler et al.,
1998). It is, however, unclear how the Rho-mediated path-
way is regulated through receptors.
The TXA2 mimetic U46619 caused a rapid phosphoryla-
tion of MLC in wild-type and Gaq-deficient platelets (see
Fig. 7). Since U46619 does not lead to elevation of [Ca21]i
in the absence of Gaq (Offermanns et al., 1997b) and since
Rho-kinase inhibitor Y-27632 and C3 exoenzyme inhibited
U46619-induced MLC phosphorylation in Gaq-deficient
platelets, we conclude that a Rho/Rho-kinase—mediated
pathway regulating MLC phosphorylation operates in
platelets. Consistent with this, the Rho-kinase p160ROCK
has been shown to be phosphorylated upon activation of
human platelets in an aIIbb3-integrin—independent way
(Fujita et al., 1997). In addition, Rho and Rho-kinase can
be coimmunoprecipitated with the myosin-binding subunit
of myosin phosphatase from human platelets, and treat-
ment of platelets with a TXA2-mimetic leads to rapid
phosphorylation and inactivation of myosin phosphatase
(Nakai et al., 1997). Conflicting data exist with regard to
the role of Rho in early platelet activation as determined
by C3 exoenzyme treatment. This is most likely due to the
difficulties associated with the length of incubation and
the high concentration of C3 exoenzyme required to inac-
tivate a sufficient fraction of Rho. Although partial inacti-
vation of the RhoA pool in human platelets by C3 exoen-
zyme has been shown to inhibit platelet activation (Morii
et al., 1992), a recent report showed that ADP ribosylation
of z90% of Rho in human platelets did not affect inside-
out signaling of integrin aIIbb3, ligand-induced aggregation
and F-actin content (Leng et al., 1998). Our data clearly
support a role of Rho in early platelet activation.
In wild-type platelets in which U46619 induces an ele-
vation of [Ca21]i and most likely leads to Ca21/calmodu-
lin-MLCK—mediated MLC phosphorylation, Rho-kinase
blocker Y-27632 and C3 exoenzyme also inhibited MLC
phosphorylation induced by U46619. Interestingly, both
agents appeared to be less potent in wild-type platelets
than in Gaq-deficient platelets (see Fig. 7, D—F). This sug-
gests that both, Ca21-mediated activation of MLCK and
inhibition of myosin phosphatase through Rho/Rho-kinase
may synergistically increase MLC phosphorylation in acti-
vated wild-type platelets. In contrast, receptor-mediated
MLC phosphorylation in Gaq-deficient platelets depends
on the Ca21-independent, Rho-mediated pathway. Since
shape change could be inhibited by the C3 exoenzyme as
well as by Y-27632 in Gaq-deficient platelets (see Figs. 1
and 2) we suggest that Rho/Rho-kinase—mediated MLC
phosphorylation is involved in TXA2 receptor-induced
platelet shape change.
Cyclic nucleotides like cAMP and cGMP mediate physi-
ological inhibition of platelet activation through activation
of cAMP- and cGMP-dependent kinases. Although ana-
logues of both cyclic nucleotides can block full platelet
activation, only cAMP analogues inhibit platelet shape
change (Matsuoka et al., 1989; Menshikov et al., 1993).
Similarly, we observed that the cAMP analogue Sp-5,6-
DCl-cBIMPS but not the cGMP analogue 8-pCPT-cGMP
inhibited TXA2 receptor-G12/G13—mediated shape change
and MLC phosphorylation in Gaq-deficient platelets (see
Figs. 2 and 7). Inhibition of MLC phosphorylation by Sp-
5,6-DCl-cBIMPS but not by 8-pCPT-cGMP suggests that
the Rho/Rho-kinase—mediated signaling cascade may be
inhibited by the cAMP-dependent pathway. A similar
role of cAMP was suggested for the inhibition of Rho/
Rho-kinase—mediated neurite remodeling and morphol-
ogy change in epithelial-like cells (Hirose et al., 1998; Dong
et al., 1998).
Rho has been shown to be regulated by the activated
a-subunits of G12 and G13 (Buhl et al., 1995; Gohla et al.,
1998; Kozasa et al., 1998). Since G12 and G13 are the only
G proteins activated through TXA2 receptors in Gaq-defi-
cient platelets and since TXA2 receptor-mediated MLC
phosphorylation in Gaq-deficient platelets was inhibited
by C3 exoenzyme and Rho-kinase inhibitor Y-27632 we
suggest that TXA2 receptor-induced G12/G13 activation re-
sults in MLC phosphorylation through Rho-mediated acti-
vation of Rho-kinase. Activated Rho-kinase may phos-
phorylate MLC directly or act through phosphorylation
and inhibition of myosin phosphatase. Additional, syner-
gistic regulation of MLC phosphorylation in wild-type
platelets occurs through Gq-mediated activation of MLCK.
The mechanism by which G12/G13 activate Rho remains to
be elucidated. Epidermal growth factor tyrosine kinase
has recently been involved in the Ga13-induced Rho-depen-
dent actin stress fiber formation in fibroblasts (Gohla et
al., 1998). However, various tyrosine kinase inhibitors
were unable to block TXA2 receptor-induced, G12/G13-
mediated MLC phosphorylation in Gaq-deficient platelets
(data not shown). This suggests that in platelets, G12/G13-
induced Rho activation is not mediated by receptor- or
nonreceptor-tyrosine kinases. Another possibility is that
regulation of Rho by G12/G13 is mediated by a Rho-spe-
cific GEF. Genetic evidence in Drosophila showed that
the Drosophila RhoGEF, DRhoGEF2, functions down-
stream of the Drosophila G12/G13 homologue concertina
(Barrett et al., 1997), and it has recently been shown that
the related mammalian RhoGEF, p115 RhoGEF, can di-
rectly link Ga13 to the regulation of Rho (Hart et al., 1998;
Kozasa et al., 1998).
Using Gaq-deficient platelets which do not aggregate
and secrete but undergo shape change in response to vari-
ous stimuli, we show that activation of G12/G13 is sufficient
to induce platelet shape change. Thus, different G pro-
tein—mediated signaling pathways appear to be specifically
involved in the regulation of distinct processes during re-
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ceptor-induced platelet activation. Although Gq is neces-
sary for full platelet activation including aggregation and
secretion, activation of Gi may counteract anti-aggrega-
tory influences through inhibition of adenylyl cyclase, and
G12/G13 appear to be centrally involved in the platelet
shape change response. Our data also indicate that G12/G13
can link receptors to tyrosine kinases as well as to Rho/
Rho-kinase—mediated regulation of MLC phosphoryla-
tion, and we provide evidence that the latter pathway par-
ticipates in the receptor-mediated induction of platelet
shape change.
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